{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:22:03Z","timestamp":1792297323979,"version":"4.4.0"},"reference-count":73,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Background: Current drug therapy for myelofibrosis does not alter the natural course of the disease or prolong survival, and allogeneic stem cell transplantation is the only curative treatment modality. For over a decade, the Janus kinase (JAK) inhibitor ruxolitinib has been the standard of care. More recently, newer-generation JAK inhibitors have joined the ranks of accepted treatment options. Objectives: The primary goal of treatment is to reduce spleen size and minimize disease-related symptoms. Prognostic scoring systems are used to designate patients as being at lower or higher risk. For transplant-eligible patients, transplant is offered to those with a bridge of a JAK inhibitor; patients who are not eligible for transplant are usually offered long-term therapy with a JAK inhibitor. Limited disease-modifying activity, dose-limiting cytopenias, and other adverse effects have contributed to discontinuation of JAK inhibitor treatment. Conclusions: Novel JAK inhibitors and combination approaches are currently being explored to overcome these shortcomings. Further research will be essential to establish optimal therapeutic approaches in first-line and subsequent treatments.<\/jats:p>","DOI":"10.3390\/hematolrep16040067","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T10:53:45Z","timestamp":1730285625000},"page":"698-713","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment Strategies Used in Treating Myelofibrosis: State of the Art"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3987-419X","authenticated-orcid":false,"given":"Massimo","family":"Martino","sequence":"first","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3982-4141","authenticated-orcid":false,"given":"Martina","family":"Pitea","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Sgarlata","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1597-1913","authenticated-orcid":false,"given":"Ilaria Maria","family":"Delfino","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cogliandro","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Scopelliti","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violetta","family":"Marafioti","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Polimeni","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4739-349X","authenticated-orcid":false,"given":"Gaetana","family":"Porto","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5857-7247","authenticated-orcid":false,"given":"Giorgia","family":"Policastro","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Utano","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Pellicano","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Leanza","sequence":"additional","affiliation":[{"name":"Pharmacy Unit, Grande Ospedale Metropolitano \u2018Bianchi-Melacrino-Morelli\u2019, 89128 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Alati","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","article-title":"Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis","volume":"129","author":"Guglielmelli","year":"2017","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"101735","DOI":"10.18632\/oncotarget.21594","article-title":"Clinical course and outcome of essential thrombocythemia and prefibrotic myelofi- brosis according to the revised WHO 2016 diagnostic criteria","volume":"8","author":"Rumi","year":"2017","journal-title":"Oncotarget"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23690","article-title":"How common are myeloproliferative neoplasms? A systematic review and meta-analysis","volume":"89","author":"Titmarsh","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.hoc.2020.11.005","article-title":"Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms","volume":"35","author":"Shallis","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1080\/10428194.2021.1992756","article-title":"Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States","volume":"63","author":"Verstovsek","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ejh.12256","article-title":"Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union","volume":"92","author":"Moulard","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Price, G.L., Davis, K.L., Karve, S., Pohl, G., and Walgren, R.A. (2014). Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090299"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14740\/jh1042","article-title":"Acute Myeloid Leukemia Following Myeloproliferative Neoplasms: A Review of What We Know, What We Do Not Know, and Emerging Treatment Strategies","volume":"11","author":"McKinnell","year":"2022","journal-title":"J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.2012.42.0240","article-title":"Improving survival trends in primary myelofibrosis: An international study","volume":"30","author":"Cervantes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1056\/NEJMe1115119","article-title":"Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms","volume":"366","author":"Tefferi","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood-2011-11-395228","article-title":"JAK inhibitors for myeloproliferative neoplasms: Clarifying facts from myths","volume":"119","author":"Tefferi","year":"2012","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/ajh.25053","article-title":"Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/cncr.29842","article-title":"The evolution and clinical relevance of prognostic classification systems in myelofibrosis","volume":"122","author":"Bose","year":"2016","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients with Primary Myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis","volume":"16","author":"Ballen","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.16462","article-title":"Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts","volume":"189","author":"Griesshammer","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs. best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","article-title":"Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: A snapshot of 1144 patients in the JUMP trial","volume":"101","author":"Griesshammer","year":"2016","journal-title":"Haematologica"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.13379","article-title":"Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: Results of the UK ROBUST Trial","volume":"170","author":"Mead","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/hon.2429","article-title":"Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study","volume":"36","author":"Palandri","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.leukres.2018.10.001","article-title":"Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients","volume":"74","author":"Palandri","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00277-021-04682-x","article-title":"Real-world survival of US patients with intermediate- to high-risk myelofibrosis: Impact of ruxolitinib approval","volume":"101","author":"Verstovsek","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_35","unstructured":"JAKAFI\u00ae (Ruxolitinib) (2023). Full Prescribing Information, Incyte Corporation."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/10428194.2023.2196593","article-title":"Ten years after ruxolitinib approval for myelofibrosis: A review of clinical efficacy","volume":"64","author":"Pemmaraju","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1038\/s41375-021-01261-x","article-title":"Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: The REALISE phase 2 study","volume":"35","author":"Cervantes","year":"2021","journal-title":"Leukemia"},{"key":"ref_38","unstructured":"National Comprehensive Cancer Network (2022). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Myeloproliferative Neoplasms, Version 3, National Comprehensive Cancer Network."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2217\/fon-2022-1298","article-title":"Defining ruxolitinib failure and transition to next-line therapy for patients with myelofibrosis: A modified Delphi panel consensus study","volume":"19","author":"Mascarenhas","year":"2023","journal-title":"Future Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Harrison, C.N., Mesa, R.N., Talpaz, M., Al-Ali, H.K., Xicoy, B., Passamonti, F., Palandri, F., Benevolo, G., Vannucchi, A.M., and Mediavilla, C. (2023, January 9\u201312). Efficacy and Safety of Fedratinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Results from the Phase 3 Randomized FREEDOM2 Study. Proceedings of the 65th ASH Annual Meeting and Exposition, San Diego, CA, USA.","DOI":"10.1182\/blood-2023-173391"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"33416","DOI":"10.18632\/oncotarget.26058","article-title":"Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy","volume":"9","author":"Singer","year":"2018","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): An international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs. Best Available Therapy, Including Ruxolitinib, in Patients with Myelofibrosis: A Randomized Clinical Trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s40265-022-01718-y","article-title":"Pacritinib: First Approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-021-01157-4","article-title":"Momelotinib: An emerging treatment for myelofibrosis patients with anemia","volume":"15","author":"Chifotides","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","article-title":"Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents","volume":"129","author":"Asshoff","year":"2017","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"MOMENTUM Study Investigators. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): Results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/13543784.2020.1751121","article-title":"Investigational non-JAK inhibitors for chronic phase myelofibrosis","volume":"29","author":"Bankar","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Pemmaraju, N., Mead, A.J., Somervaille, T.C.P., McCloskey, J.K., Palandri, F., Koschmieder, S., Lavie, D., Leber, B., Yeh, S.P., and G\u00f3mez-Casares, M.T. (2023, January 9\u201312). Transform-1: A Randomized, Double-Blind, Placebo- Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis. Proceedings of the 65th ASH Annual Meeting and Exposition, San Diego, CA, USA.","DOI":"10.1182\/blood-2023-173509"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Rampal, R., Grosicki, S., Chraniuk, D., Abruzzese, E., Bose, P., Gerds, A.T., Vannucchi, A.M., Palandri, F., Lee, S.E., and Gupta, V. (2023, January 9\u201312). Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-na\u00efve patients with myelofibrosis: Results of the MANIFEST-2 randomized, double-blind, Phase 3 study. Proceedings of the 65th ASH Annual Meeting and Exposition, San Diego, CA, USA.","DOI":"10.1182\/blood-2023-179141"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Tantravahi, S.K., Kishtagari, A., Maher, K., Mohan, S., Prchal, J.Y., and Wang, X. (2023, January 9\u201312). Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Na\u00efve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification. Proceedings of the 65th ASH Annual Meeting and Exposition, San Diego, CA, USA.","DOI":"10.1182\/blood-2023-180844"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.25777","article-title":"Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure","volume":"95","author":"Harrison","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1182\/blood-2022-156669","article-title":"Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial","volume":"140","author":"Gupta","year":"2022","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/bloodadvances.2023010151","article-title":"Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis","volume":"7","author":"Oh","year":"2023","journal-title":"Blood Adv."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1182\/bloodadvances.2020003314","article-title":"Determining the recommended dose of pacritinib: Results from the PAC203 dose-finding trial in advanced myelofibrosis","volume":"4","author":"Gerds","year":"2020","journal-title":"Blood Adv."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.2147\/JEP.S110702","article-title":"Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor","volume":"8","author":"Singer","year":"2016","journal-title":"J. Exp. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00277-018-3309-6","article-title":"Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: A sponsor-independent international study","volume":"97","author":"Mascarenhas","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1182\/bloodadvances.2022007524","article-title":"The odyssey of pacritinib in myelofibrosis","volume":"6","author":"Venugopal","year":"2022","journal-title":"Blood Adv."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"7058","DOI":"10.1200\/JCO.2022.40.16_suppl.7058","article-title":"Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF)","volume":"40","author":"Pemmaraju","year":"2022","journal-title":"JCO"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41409-024-02248-9","article-title":"Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: A report from the EBMT","volume":"59","author":"Passweg","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/bloodadvances.2019001084","article-title":"Survival following allogeneic transplant in patients with myelofibrosis","volume":"4","author":"Gowin","year":"2020","journal-title":"Blood Adv."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"79073","DOI":"10.18632\/oncotarget.18674","article-title":"Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis","volume":"8","author":"Palandri","year":"2017","journal-title":"Oncotarget"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41409-024-02269-4","article-title":"Correction: Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: A registry-based study from the Chronic Malignancies Working Party of the EBMT","volume":"59","author":"Robin","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jtct.2023.09.013","article-title":"Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning","volume":"29","author":"Joseph","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bbmt.2020.01.010","article-title":"Fludarabine\/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes","volume":"26","author":"Chhabra","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Polverelli, N., Farina, M., D\u2019Adda, M., Damiani, E., Grazioli, L., Leoni, A., Malagola, M., Bernardi, S., and Russo, D. (2022). How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation. Cells, 11.","DOI":"10.3390\/cells11030553"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ajh.27274","article-title":"2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management","volume":"99","author":"Ali","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41409-022-01574-0","article-title":"Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants","volume":"57","author":"Galli","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: A consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kroger","year":"2015","journal-title":"Leukemia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1038\/s41375-021-01294-2","article-title":"Allogeneic haematopoietic cell transplantation for myelofibrosis: Proposed definitions and management strategies for graft failure, poor graft function and relapse: Best practice recommendations of the EBMT Chronic Malignancies Working Party","volume":"35","author":"McLornan","year":"2021","journal-title":"Leukemia"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/S2352-3026(22)00330-1","article-title":"Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: A Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT","volume":"10","author":"Polverelli","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1002\/cncr.34222","article-title":"The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes","volume":"128","author":"Mascarenhas","year":"2022","journal-title":"Cancer"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/16\/4\/67\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:24:00Z","timestamp":1760113440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/16\/4\/67"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":73,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["hematolrep16040067"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep16040067","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]}}}